A Phase 3 interventional study of Rosuvastatin 20mg and Placebo in Homozygous Familial Hypercholesterolemia (HoFH), sponsored by AstraZeneca. Completed at 9 sites in 7 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-04.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to establish the efficacy, safety and tolerability of rosuvastatin in children and adolescents with homozygous familial hypercholesterolemia.
This is a randomized, double-blind, placebo-controlled, multi-center, cross-over study of the efficacy, safety and tolerability rosuvastatin in children and adolescents (aged 6 to \<18 years) with homozygous familial hypercholesterolemia (HoFH). The study is designed to assess the efficacy of rosuvastatin 20 mg compared to placebo on lipids, lipoproteins and apolipoproteins in pediatric patients with HoFH. The outcome measures to be assessed include low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, apolipoprotein B (ApoB), apolipoprotein A 1 (ApoA-1) and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg or placebo. Pharmacokinetic data of the trough plasma exposure of rosuvastatin will also be assessed in these pediatric patients with HoFH.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
This study's enrollment of 20 is close to the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Browse Homozygous Familial Hypercholesterolemia studies →AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female children and adolescents (aged 6 to \<18 years) with at least 1 of the following criteria:
Documentation of genetic testing confirming 2 mutated alleles of the LDL receptor gene locus; and/or
Documented untreated LDL C >500 mg/dL (12.9 mmol/L) and triglyceride (TG) \<300 mg/dL (3.4 mmol/L) and at least 1 of the following criteria:
Documentation of HoFH in both parents by:
Negative pregnancy test (b human chorionic gonadotropin analysis) prior to baseline in females of child bearing potential:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
Drug: Rosuvastatin 20mg
6 weeks treatment during crossover
Drug: Placebo
Active drug will be taken taken orally, QD, either in the morning or in the evening
Will be taken taken orally, QD, either in the morning or in the evening
LDL-Cholesterol (mg/dL)
Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment
Time frame: Samples taken on Day 42 (week 6) and on day 84 (week 12)
LDL-Cholesterol (mmol/L)
Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment
Time frame: Samples taken on Day 42 (week 6) and on day 84 (week 12)
TC (mg/dL)
Efficacy in terms of total cholesterol (TC)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
TC (mmol/L)
Efficacy in terms of total cholesterol (TC)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
Non-HDL C (mg/dL)
Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
Non-HDL C (mmol/L)
Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
ApoB (mg/dL)
Efficacy in terms of apolipoprotein B (ApoB)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
ApoB (g/L)
Efficacy in terms of apolipoprotein B (ApoB)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
HDL-C (mg/dL)
Efficacy in terms of high density lipoprotein cholesterol (HDL C)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
HDL-C (mmol/L)
Efficacy in terms of high density lipoprotein cholesterol (HDL C)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
LDL-C, Not on Apheresis (mg/dL)
Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
LDL-C, Not on Apheresis (mmol/L)
Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
LDL-C From End of Placebo (mg/dL)
Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg
Time frame: Samples taken at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18) and Day 168 (week 24)
LDL-C From End of Placebo (mmol/L)
Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg
Time frame: Samples taken at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18) and Day 168 (week 24)
Trough Concentrations
Pharmacokinetic profile in terms of trough concentrations. Cross-over phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the cross-over phase. Maintenance phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the maintenance phase.
Time frame: Samples taken 24 hours post-dose at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18)
Adverse Events
Safety and tolerability will be described in terms of frequency and severity of adverse events
Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)
AE's Leading to Discontinuation
Safety and tolerability will be described in terms of rate of discontinuations due to adverse events
Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)
Abnormal Serum Levels
Safety and tolerability will be described in terms of abnormal serum laboratory values. The reported parameters are not the only ones measured, but rather those for which abnormailities were found
Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)
Height
Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.
Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18
Height Z-score
Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.
Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18
Weight
Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.
Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18
Tanner Stage
Stages for fem (Pubic hair, Breasts): 1. (Preadol,Preadol) 2. (Sparse, lightly pigmented, medial border of labia,Breast and papilla elevated as small mound; areolar diam incr) 3. (Darker, beginning to curl, incr amount, Breast and areola enlarged, no contour separation) 4. (Course, curly, abundant but less amount in adult,Areola and papilla form secondary mound) 5. (Adult fem triangle, spread to medial surface of thighs,Mature, nipple projects, areola part of general breast contour) For males (Pubic hair, Penis, Testes) 1=(None,Preadol,Preadol) 2=(Scanty, long, light pigm,Slight enl,Enl scrotum, pink texture alt) 3=(Darker, starts to curl, small amount,Longer,Larger) 4=(Resembles adult type, but less in quant; course, curly,Larger; glans and breadth increased in size,Larger, scrotum dark) 5=(Adult distr, spread to medial thighs,Adult size,Adult size). Progr at a normal rate is preferred. Regr is not preferred.
Time frame: Week 0 (start of cross-over)
TG (mg/dL)
Efficacy in terms of triglycerides (TG)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
TG (mmol/L)
Efficacy in terms of triglycerides (TG)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
LDL C/HDL C
Efficacy in terms of low density lipoprotein cholesterol (LDL C) / high density lipoprotein cholesterol (HDL C)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
TC/HDL C
Efficacy in terms of total cholesterol (TC) / high density lipoprotein cholesterol (HDL C)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
Non-HDL C/HDL C
Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C) / HDL C
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
ApoB/ApoA
Efficacy in terms of apolipoprotein B (ApoB) / apolipoprotein A (ApoA)
Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)
Urinalysis Abnormalitites
Safety and tolerability will be described in terms of abnormal urine laboratory values
Time frame: Week 0, week 6, week 12 and week 18
ECG Abnormalities
Safety and tolerability will be described in terms of abnormal electro cardio gram (ECG)
Time frame: Week 0
Physical Exam Abnormalitites
Safety and tolerability will be described in terms of abnormal physical examinations. Only parameters for which abnormalities were found are reported.
Time frame: Screening, Week 0, week 6, week 12 and week 18, week 24
Abnormal Vital Signs
Safety and tolerability will be described in terms of abnormal vital signs
Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)
Twenty HoFH patients were recruited to 9 centers within 8 countries (Belgium, Canada, Denmark, Israel, Malaysia, Sweden, Taiwan, and The Netherlands) that participated in the study. FSI date: 03-Nov-2014
| Milestone | Overall | Rosuva First Then Placebo | Placebo First Then Rosuva |
|---|---|---|---|
| Started | 11 | 0 | 0 |
| Completed | 10 | 0 | 0 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Milestone | Overall | Rosuva First Then Placebo | Placebo First Then Rosuva |
|---|---|---|---|
| Started | 0 | 7 | 7 |
| Completed | 0 | 6 | 7 |
| Not completed | 0 | 1 | 0 |
| Withdrew: No possibility to draw blood | 0 | 1 | 0 |
| Milestone | Overall | Rosuva First Then Placebo | Placebo First Then Rosuva |
|---|---|---|---|
| Started | 0 | 6 | 7 |
| Completed | 0 | 6 | 7 |
| Not completed | 0 | 0 | 0 |
| Milestone | Overall | Rosuva First Then Placebo | Placebo First Then Rosuva |
|---|---|---|---|
| Started | 13 | 0 | 0 |
| Completed | 13 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment
| mg/dL | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| LDL-Cholesterol (mg/dL) | 396.0 ± 195.99 | 481.4 ± 184.90 |
Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment
| mmol/L | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| LDL-Cholesterol (mmol/L) | 10.26 ± 5.076 | 12.47 ± 4.790 |
Efficacy in terms of total cholesterol (TC)
| mg/dL | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| TC (mg/dL) | 447.6 ± 195.46 | 539.0 ± 184.91 |
Efficacy in terms of total cholesterol (TC)
| mmol/L | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| TC (mmol/L) | 11.59 ± 5.063 | 13.96 ± 4.790 |
Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)
| mg/dL | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| Non-HDL C (mg/dL) | 412.1 ± 198.62 | 505.3 ± 186.39 |
Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)
| mmol/L | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| Non-HDL C (mmol/L) | 10.67 ± 5.144 | 13.09 ± 4.826 |
Efficacy in terms of apolipoprotein B (ApoB)
| mg/dL | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| ApoB (mg/dL) | 234.9 ± 107.02 | 267.9 ± 86.33 |
Efficacy in terms of apolipoprotein B (ApoB)
| g/L | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| ApoB (g/L) | 2.35 ± 1.070 | 2.68 ± 0.863 |
Efficacy in terms of high density lipoprotein cholesterol (HDL C)
| mg/dL | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| HDL-C (mg/dL) | 35.5 ± 7.29 | 33.7 ± 8.47 |
Efficacy in terms of high density lipoprotein cholesterol (HDL C)
| mmol/L | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| HDL-C (mmol/L) | 0.92 ± 0.189 | 0.87 ± 0.218 |
Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis
| mg/dL | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| LDL-C, Not on Apheresis (mg/dL) | 479.8 ± 239.07 | 594.7 ± 203.60 |
Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis
| mmol/L | C-FAS Rosuvastatin | C-FAS Placebo Not on Apheresis |
|---|---|---|
| LDL-C, Not on Apheresis (mmol/L) | 12.43 ± 6.191 | 15.40 ± 5.274 |
Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg
| mg/dL | M-FAS Rosuvastatin | M-FAS Placebo |
|---|---|---|
| End of Placebo | 472.9 ± 171.77 | 491.3 ± 215.46 |
| 6 weeks after end of Placebo | 399.4 ± 214.28 | 421.7 ± 224.49 |
| 12 weeks after end of Placebo | 345.8 ± 214.69 | 394.7 ± 178.45 |
| 18 weeks after end of Placebo | NA ± NA | 441.8 ± 260.31 |
Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg
| mmol/L | M-FAS Rosuvastatin | M-FAS Placebo |
|---|---|---|
| End of Placebo | 12.25 ± 4.449 | 12.73 ± 5.583 |
| 6 weeks after end of Placebo | 10.34 ± 5.551 | 10.92 ± 5.813 |
| 12 weeks after end of Placebo | 8.96 ± 5.558 | 10.22 ± 4.621 |
| 18 weeks after end of Placebo | NA ± NA | 11.44 ± 6.740 |
Pharmacokinetic profile in terms of trough concentrations. Cross-over phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the cross-over phase. Maintenance phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the maintenance phase.
| ng/mL | Cross-over Phase | Maintenance Phase |
|---|---|---|
| Trough Concentrations | 7.387 ± 8.11 | 4.482 ± 3.50 |
Safety and tolerability will be described in terms of frequency and severity of adverse events
| adverse events | Lead-in | Cross-over Phase | Maintenance |
|---|---|---|---|
| Any AE | 4 | 5 | 1 |
| Any TEAE | 4 | 5 | 1 |
| Any AE leading to death | 0 | 0 | 0 |
| Any SAE | 0 | 0 | 0 |
Safety and tolerability will be described in terms of rate of discontinuations due to adverse events
| adverse events | Lead-in | Cross-over Phase | Maintenance Phase |
|---|---|---|---|
| AE's Leading to Discontinuation | 0 | 0 | 0 |
Safety and tolerability will be described in terms of abnormal serum laboratory values. The reported parameters are not the only ones measured, but rather those for which abnormailities were found
| participants | Ros/Pla <LLN | Ros/Pla >ULN | Pla/Ros <LLN | Pla/Ros >ULN |
|---|---|---|---|---|
| Alanine Aminotransferase week 0 | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase week 6 | 0 | 1 | 0 | 0 |
| Alanine Aminotransferase week 12 | 0 | 0 | 0 | 1 |
| Alanine Aminotransferase week 18 | 0 | 0 | 0 | 1 |
| Alanine Aminotransferase week 24 | 0 | 1 | 0 | 0 |
| Albumin week 0 | 0 | 0 | 0 | 1 |
| Albumin week 6 | 0 | 0 | 0 | 0 |
| Albumin week 12 | 0 | 0 | 0 | 0 |
| Albumin week 18 | 0 | 0 | 0 | 1 |
| Albumin week 24 | 0 | 0 | 0 | 0 |
| Bicarbonate week 0 | 1 | 0 | 0 | 1 |
| Bicarbonate week 6 | 0 | 0 | 1 | 0 |
| Bicarbonate week 12 | 1 | 0 | 1 | 0 |
| Bicarbonate week 18 | 0 | 0 | 1 | 0 |
| Bicarbonate week 24 | 1 | 0 | 1 | 0 |
| Blood Urea Nitrogen week 0 | 1 | 0 | 0 | 0 |
| Blood Urea Nitrogen week 6 | 1 | 0 | 0 | 0 |
| Blood Urea Nitrogen week 12 | 1 | 0 | 0 | 0 |
| Blood Urea Nitrogen week 18 | 1 | 0 | 0 | 0 |
| Blood Urea Nitrogen week 24 | 0 | 0 | 0 | 0 |
| Chloride week 0 | 0 | 2 | 0 | 1 |
| Chloride week 6 | 0 | 0 | 0 | 1 |
| Chloride week 12 | 0 | 0 | 0 | 0 |
| Chloride week 18 | 0 | 1 | 0 | 1 |
| Chloride week 24 | 0 | 0 | 0 | 0 |
| Creatine Kinase week 0 | 0 | 0 | 0 | 0 |
| Creatine Kinase week 6 | 0 | 1 | 0 | 0 |
| Creatine Kinase week 12 | 0 | 0 | 0 | 0 |
| Creatine Kinase week 18 | 0 | 0 | 0 | 0 |
| Creatine Kinase week 24 | 0 | 1 | 0 | 0 |
| Glucose week 0 | 0 | 1 | 0 | 0 |
| Glucose week 6 | 0 | 0 | 0 | 1 |
| Glucose week 12 | 0 | 0 | 0 | 0 |
| Glucose week 18 | 0 | 1 | 0 | 1 |
| Glucose week 24 | 0 | 0 | 0 | 0 |
| Potassium week 0 | 0 | 0 | 0 | 1 |
| Potassium week 6 | 0 | 0 | 0 | 0 |
| Potassium week 12 | 0 | 0 | 0 | 0 |
| Potassium week 18 | 0 | 0 | 0 | 0 |
| Potassium week 24 | 0 | 0 | 0 | 0 |
| Protein week 0 | 0 | 0 | 0 | 0 |
| Protein week 6 | 0 | 0 | 0 | 0 |
| Protein week 12 | 0 | 0 | 0 | 1 |
| Protein week 18 | 0 | 0 | 0 | 0 |
| Protein week 24 | 0 | 0 | 0 | 1 |
| Sodium week 0 | 2 | 0 | 0 | 0 |
| Sodium week 6 | 1 | 0 | 0 | 0 |
| Sodium week 12 | 0 | 0 | 0 | 0 |
| Sodium week 18 | 3 | 0 | 1 | 0 |
| Sodium week 24 | 0 | 0 | 2 | 0 |
| Total Bilirubin week 0 | 0 | 0 | 0 | 0 |
| Total Bilirubin week 6 | 0 | 1 | 0 | 0 |
| Total Bilirubin week 12 | 0 | 0 | 0 | 0 |
| Total Bilirubin week 18 | 0 | 0 | 0 | 0 |
| Total Bilirubin week 24 | 0 | 0 | 0 | 0 |
| Urate week 0 | 0 | 1 | 0 | 0 |
| Urate week 6 | 0 | 1 | 0 | 1 |
| Urate week 12 | 0 | 1 | 0 | 0 |
| Urate week 18 | 0 | 1 | 0 | 1 |
| Urate week 24 | 0 | 1 | 0 | 1 |
| Ery. Mean Corpuscular HGB Concentration week 0 | 2 | 0 | 3 | 0 |
| Ery. Mean Corpuscular HGB Concentration week 6 | 0 | 0 | 2 | 0 |
| Ery. Mean Corpuscular HGB Concentration week 12 | 3 | 0 | 2 | 0 |
| Ery. Mean Corpuscular HGB Concentration week 18 | 1 | 0 | 2 | 0 |
| Ery. Mean Corpuscular HGB Concentration week 24 | 2 | 0 | 3 | 0 |
| Ery. Mean Corpuscular Hemoglobin week 0 | 1 | 0 | 3 | 0 |
| Ery. Mean Corpuscular Hemoglobin week 6 | 1 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Hemoglobin week 12 | 2 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Hemoglobin week 18 | 1 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Hemoglobin week 24 | 1 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Volume week 0 | 1 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Volume week 6 | 1 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Volume week 12 | 1 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Volume week 18 | 1 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Volume week 24 | 1 | 0 | 2 | 0 |
| Erythrocytes week 0 | 1 | 0 | 0 | 1 |
| Erythrocytes week 6 | 0 | 0 | 0 | 0 |
| Erythrocytes week 12 | 0 | 0 | 1 | 1 |
| Erythrocytes week 18 | 0 | 0 | 1 | 0 |
| Erythrocytes week 24 | 0 | 2 | 0 | 2 |
| Hematocrit week 0 | 2 | 0 | 2 | 0 |
| Hematocrit week 6 | 2 | 0 | 3 | 0 |
| Hematocrit week 12 | 1 | 0 | 2 | 0 |
| Hematocrit week 18 | 1 | 0 | 3 | 0 |
| Hematocrit week 24 | 0 | 0 | 1 | 0 |
| Hemoglobin week 0 | 2 | 0 | 3 | 0 |
| Hemoglobin week 6 | 2 | 0 | 3 | 0 |
| Hemoglobin week 12 | 1 | 0 | 3 | 0 |
| Hemoglobin week 18 | 1 | 0 | 3 | 0 |
| Hemoglobin week 24 | 0 | 0 | 2 | 0 |
| Lymphocytes/Leukocytes week 0 | 0 | 0 | 0 | 1 |
| Lymphocytes/Leukocytes week 6 | 0 | 0 | 0 | 1 |
| Lymphocytes/Leukocytes week 12 | 0 | 0 | 0 | 1 |
| Lymphocytes/Leukocytes week 18 | 0 | 1 | 0 | 1 |
| Lymphocytes/Leukocytes week 24 | 0 | 1 | 0 | 1 |
| Neutrophils, Segmented/Leukocytes week 0 | 0 | 0 | 0 | 0 |
| Neutrophils, Segmented/Leukocytes week 6 | 0 | 0 | 0 | 0 |
| Neutrophils, Segmented/Leukocytes week 12 | 0 | 0 | 0 | 0 |
| Neutrophils, Segmented/Leukocytes week 18 | 1 | 0 | 0 | 0 |
| Neutrophils, Segmented/Leukocytes week 24 | 1 | 0 | 0 | 0 |
| Neutrophils/Leukocytes week 0 | 0 | 0 | 0 | 0 |
| Neutrophils/Leukocytes week 6 | 1 | 0 | 0 | 0 |
| Neutrophils/Leukocytes week 12 | 0 | 0 | 0 | 0 |
| Neutrophils/Leukocytes week 18 | 0 | 0 | 0 | 0 |
| Neutrophils/Leukocytes week 24 | 0 | 0 | 0 | 0 |
| Platelets week 0 | 0 | 1 | 0 | 0 |
| Platelets week 6 | 0 | 0 | 0 | 1 |
| Platelets week 12 | 0 | 0 | 0 | 0 |
| Platelets week 18 | 0 | 0 | 0 | 0 |
| Platelets week 24 | 0 | 0 | 0 | 1 |
Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.
| cm | Ros/Pla | Pla/Ros |
|---|---|---|
| Height (cm) week 0 | 144.0 ± 17.82 | 140.9 ± 15.70 |
| Height (cm) week 6 | 144.9 ± 17.70 | 141.1 ± 16.11 |
| Height (cm) week 12 | 145.7 ± 18.07 | 142.0 ± 17.17 |
| Height (cm) week 18 | 146.9 ± 17.68 | 142.3 ± 16.99 |
| Height (cm) week 24 | 147.1 ± 17.94 | 143.5 ± 17.58 |
Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.
| ratio | Ros/Pla | Pla/Ros |
|---|---|---|
| Height z-score week 0 | -0.42 ± 1.697 | -0.75 ± 1.555 |
| Height z-score week 6 | -0.29 ± 1.703 | -0.71 ± 1.644 |
| Height z-score week 12 | -0.18 ± 1.742 | -0.70 ± 1.776 |
| Height z-score week 18 | 0.00 ± 1.721 | -0.65 ± 1.757 |
| Height z-score week 24 | 0.04 ± 1.752 | -0.49 ± 1.758 |
Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.
| kg | Ros/Pla | Pla/Ros |
|---|---|---|
| Weight (kg) week 0 | 37.39 ± 12.731 | 40.19 ± 16.520 |
| Weight (kg) week 6 | 38.14 ± 13.577 | 40.36 ± 16.462 |
| Weight (kg) week 12 | 38.63 ± 14.426 | 42.30 ± 18.651 |
| Weight (kg) week 18 | 39.31 ± 14.588 | 42.50 ± 17.990 |
| Weight (kg) week 24 | 39.90 ± 14.550 | 43.00 ± 17.867 |
Stages for fem (Pubic hair, Breasts): 1. (Preadol,Preadol) 2. (Sparse, lightly pigmented, medial border of labia,Breast and papilla elevated as small mound; areolar diam incr) 3. (Darker, beginning to curl, incr amount, Breast and areola enlarged, no contour separation) 4. (Course, curly, abundant but less amount in adult,Areola and papilla form secondary mound) 5. (Adult fem triangle, spread to medial surface of thighs,Mature, nipple projects, areola part of general breast contour) For males (Pubic hair, Penis, Testes) 1=(None,Preadol,Preadol) 2=(Scanty, long, light pigm,Slight enl,Enl scrotum, pink texture alt) 3=(Darker, starts to curl, small amount,Longer,Larger) 4=(Resembles adult type, but less in quant; course, curly,Larger; glans and breadth increased in size,Larger, scrotum dark) 5=(Adult distr, spread to medial thighs,Adult size,Adult size). Progr at a normal rate is preferred. Regr is not preferred.
| stage | Ros/Pla | Pla/Ros |
|---|---|---|
| Tanner stage week 0 | 2.0 ± 1.41 | 1.7 ± 1.11 |
| Tanner stage week 24 | 2.3 ± 1.38 | 2.0 ± 0.2 |
Efficacy in terms of triglycerides (TG)
| mg/dL | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| TG (mg/dL) | 79.8 ± 24.48 | 119.5 ± 52.67 |
Efficacy in terms of triglycerides (TG)
| mmol/L | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| TG (mmol/L) | 0.90 ± 0.277 | 1.35 ± 0.595 |
Efficacy in terms of low density lipoprotein cholesterol (LDL C) / high density lipoprotein cholesterol (HDL C)
| ratio | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| LDL C/HDL C | 12.208 ± 7.8638 | 15.600 ± 9.1317 |
Efficacy in terms of total cholesterol (TC) / high density lipoprotein cholesterol (HDL C)
| ratio | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| TC/HDL C | 13.704 ± 8.0414 | 17.416 ± 9.5454 |
Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C) / HDL C
| ratio | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| Non-HDL C/HDL C | 12.704 ± 8.0414 | 16.416 ± 9.5454 |
Efficacy in terms of apolipoprotein B (ApoB) / apolipoprotein A (ApoA)
| ratio | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|
| ApoB/ApoA | 2.408 ± 1.3259 | 2.873 ± 1.4669 |
Safety and tolerability will be described in terms of abnormal urine laboratory values
| participants | Ros/Pla | Pla/Ros |
|---|---|---|
| Urine Protein week 0 | 3 | 2 |
| Urine Protein week 6 | 1 | 2 |
| Urine Protein week 12 | 3 | 2 |
| Urine Protein week 18 | 2 | 1 |
| Urine Protein week 24 | 2 | 1 |
| Urine Ketones week 0 | 1 | 0 |
| Urine Ketones week 6 | 0 | 0 |
| Urine Ketones week 12 | 0 | 0 |
| Urine Ketones week 18 | 0 | 1 |
| Urine Ketones week 24 | 0 | 0 |
| Urine Blood week 0 | 1 | 2 |
| Urine Blood week 6 | 2 | 1 |
| Urine Blood week 12 | 1 | 2 |
| Urine Blood week 18 | 1 | 1 |
| Urine Blood week 24 | 1 | 1 |
Safety and tolerability will be described in terms of abnormal electro cardio gram (ECG)
| participants | Safety Analysis Set | C-FAS Rosuvastatin | C-FAS Placebo |
|---|---|---|---|
| ECG Abnormalities | 0 | 0 | 0 |
Safety and tolerability will be described in terms of abnormal physical examinations. Only parameters for which abnormalities were found are reported.
| participants | Ros/Pla | Pla/Ros |
|---|---|---|
| General Appearance screening | 1 | 2 |
| General Appearance week 0 | 1 | 2 |
| General Appearance week 6 | 1 | 2 |
| General Appearance week 12 | 1 | 2 |
| General Appearance week 18 | 1 | 2 |
| General Appearance week 24 | 1 | 2 |
| Head and Neck screening | 0 | 2 |
| Head and Neck week 0 | 0 | 2 |
| Head and Neck week 6 | 0 | 2 |
| Head and Neck week 12 | 0 | 2 |
| Head and Neck week 18 | 0 | 2 |
| Head and Neck week 24 | 0 | 1 |
| Lymph Nodes screening | 0 | 0 |
| Lymph Nodes week 0 | 0 | 1 |
| Lymph Nodes week 6 | 0 | 0 |
| Lymph Nodes week 12 | 0 | 0 |
| Lymph Nodes week 18 | 0 | 0 |
| Lymph Nodes week 24 | 0 | 0 |
| Skin screening | 5 | 2 |
| Skin week 0 | 5 | 2 |
| Skin week 6 | 5 | 2 |
| Skin week 12 | 5 | 2 |
| Skin week 18 | 5 | 2 |
| Skin week 24 | 5 | 2 |
Safety and tolerability will be described in terms of abnormal vital signs
| participants | Safety Analysis Set |
|---|---|
| Abnormal Vital Signs | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lead-in | — | 0/11 (0%) | 4/11 (36.4%) |
| Cross-over | — | 0/14 (0%) | 4/14 (28.6%) |
| Maintenance | — | 0/13 (0%) | 1/13 (7.7%) |
| Event | Lead-in | Cross-over | Maintenance |
|---|---|---|---|
| Influenza like illnessGeneral disorders | 2/11 | 2/14 | 0/13 |
| Peripheral swellingGeneral disorders | 1/11 | 0/14 | 0/13 |
| Abdominal pain upperGastrointestinal disorders | 1/11 | 0/14 | 0/13 |
| Blood bicarbonate decreasedInvestigations | 0/11 | 0/14 | 1/13 |
| InfluenzaInfections and infestations | 0/11 | 1/14 | 0/13 |
| NasopharyngitisInfections and infestations | 0/11 | 1/14 | 0/13 |
| Chest painGeneral disorders | 0/11 | 1/14 | 0/13 |
Number of baseline participants are not the same as started as there was a lead-in phase in between and as 6 of the 20 patients starting did not enter the cross-over phase, the beginning of which defines the baseline.
| Age, Continuous(Years) | Cross-over |
|---|---|
| Mean | 10.9 ± 2.70 |
| Sex: Female, Male(Participants) | Cross-over |
|---|---|
| Female | 7 |
| Male | 7 |
The record gives a start of Nov 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin
Homozygous Familial Hypercholesterolemia →